BCAX
Bicara Therapeutics Inc. Common Stock
$29.49
+0.50
(+1.72%)
Mkt Cap
1.62B
Volume
121,522
52W Range
9.465-30.99
Sector
Healthcare
Beta
-0.81
EPS (TTM)
-2.78
P/E Ratio
-6.68
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Net Income | (137.95M) | (68.00M) | (51.98M) | (37.84M) |
| EPS | -2.52 | -1.25 | -1.00 | -0.73 |
| Free Cash Flow | (107.11M) | (74.82M) | (46.21M) | (32.27M) |
| FCF / Share | -1.96 | -1.37 | -0.89 | -0.62 |
| Operating CF | (106.83M) | (74.75M) | (45.63M) | (32.08M) |
| Total Assets | 430.99M | 569.20M | 233.98M | 6.70M |
| Total Debt | 1.71M | 738,000 | 657,000 | 0 |
| Cash & Equiv | 96.69M | 489.71M | 230.44M | 4.16M |
| Book Value | 401.45M | 491.88M | 218.51M | (17.28M) |
| Return on Equity | -0.34 | -0.14 | -0.24 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (56.21M) | (37.39M) | (36.33M) | (27.39M) | (36.85M) | (20.96M) | (17.48M) | (17.05M) | (12.51M) | (12.44M) | (22.84M) | (8.35M) |
| EPS | -0.93 | -0.68 | -0.67 | -0.50 | -0.68 | -0.38 | -0.32 | -0.27 | -0.27 | -0.23 | -0.42 | -0.15 |
| Free Cash Flow | (37.57M) | (24.12M) | (29.29M) | (25.59M) | (28.11M) | (30.07M) | (17.23M) | (12.93M) | (14.59M) | (8.47M) | (10.68M) | (13.53M) |
| FCF / Share | -0.62 | -0.44 | -0.54 | -0.47 | -0.52 | -0.55 | -0.32 | -0.24 | -0.27 | -0.16 | -0.20 | -0.25 |
| Operating CF | (37.51M) | (23.89M) | (29.25M) | (25.59M) | (28.11M) | (30.03M) | (17.22M) | (12.91M) | (14.59M) | (8.04M) | (10.53M) | (13.53M) |
| Total Assets | 553.60M | 430.99M | 424.69M | 453.59M | 478.08M | 569.20M | 524.17M | 208.78M | 208.78M | 233.98M | N/A | N/A |
| Total Debt | 1.44M | 1.71M | 1.98M | 2.24M | 591,000 | 738,000 | 445,000 | 517,000 | 517,000 | 657,000 | N/A | N/A |
| Cash & Equiv | 323.46M | 96.69M | 171.67M | 436.61M | 462.06M | 489.71M | 520.76M | 203.85M | 203.85M | 230.44M | N/A | N/A |
| Book Value | 513.96M | 401.45M | 402.78M | 435.20M | 458.96M | 491.88M | 509.56M | (174.78M) | 192.50M | 218.51M | N/A | N/A |
| Return on Equity | -0.11 | -0.09 | -0.09 | -0.06 | -0.08 | -0.04 | -0.03 | N/A | -0.06 | -0.06 | N/A | N/A |
BCAX News
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript